PURPOSE:Cancer-related fatigue (CRF) is the most common symptom in patients with advanced cancer. The primary objective of this prospective, randomized, double-blind, placebo-controlled study was to compare the effect of dexamethasone and placebo on CRF. PATIENTS AND METHODS: Patients with advanced cancer with ≥ three CRF-related symptoms (ie, fatigue, pain, nausea, loss of appetite, depression, anxiety, or sleep disturbance) ≥ 4 of 10 on the Edmonton Symptom Assessment Scale (ESAS) were eligible. Patients were randomly assigned to either dexamethasone 4 mg or placebo orally twice per day for 14 days. The primary end point was change in the Functional Assessment of Chronic Illness-Fatigue (FACIT-F) subscale from baseline to day 15. Secondary outcomes included anorexia, anxiety, depression, and symptom distress scores. RESULTS: A total of 84 patients were evaluable (dexamethasone, 43; placebo, 41). Mean (± standard deviation) improvement in the FACIT-F subscale at day 15 was significantly higher in the dexamethasone than in the placebo group (9 [± 10.3] v 3.1 [± 9.59]; P = .008). The improvement in FACIT-F total quality-of-life scores was also significantly better for the dexamethasone group at day 15 (P = .03). The mean differences in the ESAS physical distress scores at day 15 were significantly better for the dexamethasone group (P = .013, respectively). No differences were observed for ESAS overall symptom distress (P = .22) or psychological distress score (P = .76). Frequency of adverse effects was not significantly different between groups (41 of 62 v 44 of 58; P = .14). CONCLUSION:Dexamethasone is more effective than placebo in improving CRF and quality of life in patients with advanced cancer.
RCT Entities:
PURPOSE:Cancer-related fatigue (CRF) is the most common symptom in patients with advanced cancer. The primary objective of this prospective, randomized, double-blind, placebo-controlled study was to compare the effect of dexamethasone and placebo on CRF. PATIENTS AND METHODS: Patients with advanced cancer with ≥ three CRF-related symptoms (ie, fatigue, pain, nausea, loss of appetite, depression, anxiety, or sleep disturbance) ≥ 4 of 10 on the Edmonton Symptom Assessment Scale (ESAS) were eligible. Patients were randomly assigned to either dexamethasone 4 mg or placebo orally twice per day for 14 days. The primary end point was change in the Functional Assessment of Chronic Illness-Fatigue (FACIT-F) subscale from baseline to day 15. Secondary outcomes included anorexia, anxiety, depression, and symptom distress scores. RESULTS: A total of 84 patients were evaluable (dexamethasone, 43; placebo, 41). Mean (± standard deviation) improvement in the FACIT-F subscale at day 15 was significantly higher in the dexamethasone than in the placebo group (9 [± 10.3] v 3.1 [± 9.59]; P = .008). The improvement in FACIT-F total quality-of-life scores was also significantly better for the dexamethasone group at day 15 (P = .03). The mean differences in the ESAS physical distress scores at day 15 were significantly better for the dexamethasone group (P = .013, respectively). No differences were observed for ESAS overall symptom distress (P = .22) or psychological distress score (P = .76). Frequency of adverse effects was not significantly different between groups (41 of 62 v 44 of 58; P = .14). CONCLUSION:Dexamethasone is more effective than placebo in improving CRF and quality of life in patients with advanced cancer.
Authors: Heather S L Jim; Kelly A Hyland; Ashley M Nelson; Javier Pinilla-Ibarz; Kendra Sweet; Marieke Gielissen; Hailey Bulls; Aasha I Hoogland; Paul B Jacobsen; Hans Knoop Journal: Cancer Date: 2019-09-25 Impact factor: 6.860
Authors: Eudocia Q Lee; Alona Muzikansky; Jan Drappatz; Santosh Kesari; Eric T Wong; Camilo E Fadul; David A Reardon; Andrew D Norden; Lakshmi Nayak; Mikael L Rinne; Brian M Alexander; Nils D Arvold; Lisa Doherty; Jennifer Stefanik; Debra LaFrankie; Sandra F Ruland; Julee Pulverenti; Katrina H Smith; Sarah C Gaffey; Samantha Hammond; Patrick Y Wen Journal: Neuro Oncol Date: 2016-02-21 Impact factor: 12.300
Authors: Leorey N Saligan; Karin Olson; Kristin Filler; David Larkin; Fiona Cramp; Sriram Yennurajalingam; Yennu Sriram; Carmen P Escalante; Auro del Giglio; Kord M Kober; Jayesh Kamath; Oxana Palesh; Karen Mustian Journal: Support Care Cancer Date: 2015-05-15 Impact factor: 3.603
Authors: Meera Agar; Eng-Siew Koh; Emma Gibbs; Elizabeth H Barnes; Elizabeth Hovey; Ann Livingstone; Kate Sawkins; Richard Chye; Melanie R Lovell; Katherine Clark; Janette Vardy; Madeleine King Journal: Support Care Cancer Date: 2015-08-21 Impact factor: 3.603
Authors: Ann M Berger; Kathi Mooney; Amy Alvarez-Perez; William S Breitbart; Kristen M Carpenter; David Cella; Charles Cleeland; Efrat Dotan; Mario A Eisenberger; Carmen P Escalante; Paul B Jacobsen; Catherine Jankowski; Thomas LeBlanc; Jennifer A Ligibel; Elizabeth Trice Loggers; Belinda Mandrell; Barbara A Murphy; Oxana Palesh; William F Pirl; Steven C Plaxe; Michelle B Riba; Hope S Rugo; Carolina Salvador; Lynne I Wagner; Nina D Wagner-Johnston; Finly J Zachariah; Mary Anne Bergman; Courtney Smith Journal: J Natl Compr Canc Netw Date: 2015-08 Impact factor: 11.908